Search the Newsreel

Q3 Earnings Forecast for TNYA Issued By HC Wainwright

Tenaya Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Tenaya Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The report is provided by Refinitiv and is available through TradingView News. Users can access the full article and more news from Reuters on the platform.

Tenaya Therapeutics (TNYA) Gains 5.81% as Biotech Stock Holds Above Critical $0.74 Support - Zero Gamma Level

Tenaya Therapeutics Q2 net loss widens on impairment charge

Tenaya Therapeutics (TNYA) reported a widening net loss in the second quarter due to an impairment charge. This financial result was covered by Reuters and is available on TradingView News. Investors can find further details and analysis on the TradingView platform.

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics has announced its financial results for the second quarter of 2026 and provided an update on its business operations. This report likely details the company's financial performance, key developments in its therapeutic pipeline, and strategic outlook for the coming months.

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Tenaya Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference, with members of management hosting 1x1 investor meetings from August 11-12, 2026. Eric Hyllengren, Tenaya's Chief Financial Officer, will also hold a fireside chat on August 11, 2026, which will be webcast …

Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday

Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results

Tenaya CFO Eric Hyllengren to Speak at Boston Conference

Tenaya Therapeutics (NASDAQ: TNYA) announced that its CFO, Eric Hyllengren, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 12:30 p.m. ET. The company will also host 1x1 investor meetings during the conference, which …

Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Tenaya Therapeutics Inc (TNYA). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article includes current stock information for TNYA.

Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tenaya Therapeutics Inc (TNYA), highlighting its major shareholders and institutional holdings. It provides a breakdown of share proportions by specific investors and by shareholder types, along with a historical overview of institutional shareholding changes and recent shareholder …

Tenaya Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNYA

This article provides a basic overview of Tenaya Therapeutics, Inc. (NASDAQ: TNYA) financial information, specifically its revenue breakdown. It indicates that further details can be found under the "Segments" section of their financial data on the TradingView platform. The content is primarily navigational and …

TradingKey

This article presents the quarterly and annual income statements for Tenaya Therapeutics Inc. (TNYA), detailing its revenue, operating expenses, and net income figures over several fiscal periods. It also includes an FAQ section explaining how to interpret the income statement, distinguishing between quarterly and …

Tenaya Therapeutics Inc (TNYA) Institutional Confidence

This article provides key institutional shareholding data for Tenaya Therapeutics Inc (TNYA), detailing the shares held and percentage change for major institutional investors. Firms like The Column Group LP, Millennium Management LLC, and BlackRock Institutional Trust Company, N.A., are listed with their holdings, offering …

Tenaya Therapeutics Inc|Price:0.775|Chg%:+0.002

This TradingKey page provides an overview of Tenaya Therapeutics Inc (TNYA) stock, including its current price of $0.775, a slight increase of 0.25%. The page highlights that a stock score is not available due to insufficient data and explains how TradingKey generates various scores …

Tenaya Therapeutics (TNYA) Q1 2026 Earnings: Wider Loss but Stock Gains as Pipeline Progress Offsets Financial Miss - Earnings Season Review

Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price

Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to its newly appointed CFO, Eric Hyllengren, for 1.65 million shares, and an additional 187,200 shares to two non-executive employees. These inducement grants, made under the company's 2024 Inducement Equity Incentive Plan, have an exercise price of $0.8365 …

Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report

Tenaya Therapeutics, Inc.'s Chief Financial Officer, Eric J Hyllengren, has filed an initial Form 3 insider ownership report. The filing indicates no buy or sell transactions, no derivative positions, and a neutral net buy/sell status. This Form 3 establishes Hyllengren as an insider subject …

Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options

Tenaya Therapeutics (TNYA) granted its Chief Financial Officer, Eric J. Hyllengren, a stock option for 1,650,000 shares of common stock with an exercise price of $0.8365 per share. This option was issued under the 2024 Inducement Equity Incentive Plan, will vest 25% after one …

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics (NASDAQ: TNYA) announced inducement grants of stock options to its new Chief Financial Officer, Eric Hyllengren, and two other non-executive employees. The grants, totaling 1,650,000 shares for Hyllengren and 187,200 for other employees, were made in accordance with NASDAQ Listing Rule 5635(c)(4) …